Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zedira GmbH manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 3 pending office actions currently active. These 3 pending office actions are distributed among 2 distinct examiners and 2 distinct art units, showing some concentration in the prosecution of its applications. This structure suggests that while the company has multiple active matters, they are being handled by a small group of 2 distinct examiners within the biotechnology sector.
MCMILLIAN, KARA RENITA is the busiest examiner for the company, handling 2 busiest examiner pending office actions. Since there are 3 pending office actions in total, she is responsible for the majority of the current workload. The remaining action is handled by the other distinct examiner. For the company, this means that the prosecution outcomes are heavily influenced by the decisions of MCMILLIAN, KARA RENITA. Practitioners should prioritize understanding her specific requirements to efficiently resolve the 2 busiest examiner pending office actions across the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 2 | 30.9% | +37.9% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573802 | INHIBITORS OF TRANSGLUTAMINASES | JARRELL, NOBLE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573802 | INHIBITORS OF TRANSGLUTAMINASES | JARRELL, NOBLE E | — |
| 18572114 | INHIBITORS OF TRANSGLUTAMINASES | MCMILLIAN, KARA RENITA | — |
| 18572134 | INHIBITORS OF TRANSGLUTAMINASES | MCMILLIAN, KARA RENITA | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573802 | INHIBITORS OF TRANSGLUTAMINASES | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18572114 | INHIBITORS OF TRANSGLUTAMINASES | MCMILLIAN, KARA RENITA | 1623 | §112Other | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18572134 | INHIBITORS OF TRANSGLUTAMINASES | MCMILLIAN, KARA RENITA | 1623 | §112Other | Non-Final OA | — | Pending | Dec 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZedira GmbH has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kara Renita Mcmillian has the most, with 2 of Zedira GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
